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Abstract. 
 
Focal adhesion kinase–null (FAK
 
2
 
/
 
2
 
) ﬁbro-
blasts exhibit morphological and motility defects that
are reversed by focal adhesion kinase (FAK) reexpres-
sion. The FAK-related kinase, proline-rich tyrosine ki-
nase 2 (Pyk2), is expressed in FAK
 
2
 
/
 
2
 
 cells, yet it exhib-
its a perinuclear distribution and does not functionally
substitute for FAK. Chimeric Pyk2/FAK proteins were
created and expressed in FAK
 
2
 
/
 
2
 
 cells to determine the
impact of Pyk2 localization to focal contacts. Whereas
an FAK/Pyk2 COOH-terminal (CT) domain chimera
was perinuclear distributed, stable expression of a Pyk2
chimera with the FAK-CT domain (Pyk2/FAK-CT) lo-
calized to focal contact sites and enhanced ﬁbronectin
(FN)-stimulated haptotactic cell migration equal to
FAK-reconstituted cells. Disruption of paxillin binding
to the FAK-CT domain (S-1034) inhibited Pyk2/FAK-
CT localization to focal contacts and its capacity to pro-
mote cell motility. Paxillin binding to the FAK-CT was
necessary but not sufﬁcient to mediate the indirect as-
 
sociation of FAK or Pyk2/FAK-CT with a 
 
b
 
1-integrin–
containing complex. Both FAK and Pyk2/FAK-CT but
not Pyk2/FAK-CT S-1034 reconstituted FAK
 
2
 
/
 
2
 
 cells,
exhibit elevated FN-stimulated extracellular signal–
regulated kinase 2 (ERK2) and c-Jun NH
 
2
 
-terminal ki-
nase (JNK) kinase activation. FN-stimulated FAK or
Pyk2/FAK-CT activation enhanced both the extent and
duration of FN-stimulated ERK2 activity which was
necessary for cell motility. Transient overexpression of
the FAK-CT but not FAK-CT S-1034 domain inhibited
both FN-stimulated ERK2 and JNK activation as well
as FN-stimulated motility of Pyk2/FAK-CT reconsti-
tuted cells. These gain-of-function studies show that the
NH
 
2
 
-terminal and kinase domains of Pyk2 can func-
tionally substitute for FAK in promoting FN-stimulated
signaling and motility events when localized to 
 
b
 
-inte-
grin–containing focal contact sites via interactions me-
diated by the FAK-CT domain.
Key words: FAK • Pyk2 • cell migration • integrins •
signaling
 
Introduction
 
The regulation of integrin-stimulated (haptotactic) cell mi-
gration is complex and not well characterized at the molecu-
lar level (Horwitz and Parsons, 1999). Haptotaxis differs
from chemotaxis-driven cell migration in that no soluble
growth factors are required to generate motility signaling
events (Vuori and Ruoslahti, 1999). The focal adhesion ki-
 
nase (FAK),
 
1
 
 protein tyrosine kinase (PTK), colocalizes
with integrin receptors at cell substratum contact sites
termed focal adhesions and is activated by integrin binding
to extracellular matrix proteins (for review see Schlaepfer et
al., 1999). Null mutations of either the murine fibronectin
(FN) or FAK genes result in similar embryonic lethal phe-
notypes, and this genetic connection supports a role for
FAK in transducing signals downstream of FN–integrin in-
 
teractions such as those stimulated by the 
 
a
 
5
 
b
 
1-integrin het-
erodimer (Ilic et al., 1995).
Proline-rich tyrosine kinase 2 (Pyk2) is a FAK-related
PTK variously called cell adhesion kinase 
 
b 
 
(CAK
 
b
 
), re-
lated adhesion focal tyrosine kinase (RAFTK), or cal-
cium-dependent PTK (CADTK) (for review see Avraham
et al., 2000). Pyk2 and FAK share the same overall struc-
ture with a highly conserved central catalytic domain,
phosphorylation/docking sites for Src homology (SH)2 do-
main–containing proteins (Schlaepfer et al., 1994; Lev et
al., 1995), proline-rich binding sites for SH3 domain–con-
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taining proteins (Astier et al., 1997; Polte and Hanks,
1997), and related NH
 
2
 
-terminal (NT) band 4.1, ezrin, ra-
dixin, and moesin (FERM) homology regions (Girault et
al., 1999). Whereas in vitro results have suggested that the
FAK FERM domain may bind to 
 
b
 
-integrin cytoplasmic
domain sequences (Schaller et al., 1995), recent studies
have shown that the FAK COOH-terminal (CT) but not
FAK-NT domain forms a complex with 
 
b
 
1-integrins in
vivo (Chen et al., 2000; Sieg et al., 2000). A region termed
the focal adhesion targeting (FAT) motif within the FAK-
CT domain promotes the localization of FAK to sites of
integrin receptor clustering (Hildebrand et al., 1993) and is
also important for binding the 
 
b
 
-integrin–associated pro-
tein, talin (Chen et al., 1995). Both FAK and Pyk2 contain
conserved sites within their CT domains for binding the
 
a
 
-integrin–associated protein, paxillin (Tachibana et al.,
1995; Liu et al., 1999). However, Pyk2 does not strongly lo-
calize to focal contact sites in fibroblasts or smooth muscle
cells (Sieg et al., 1998; Zheng et al., 1998).
FAK-null (FAK
 
2
 
/
 
2
 
) fibroblasts exhibit a rounded mor-
phology, increased numbers of focal contacts, and are re-
fractory to migratory stimuli (Ilic et al., 1995). Pyk2 ex-
pression is elevated in FAK
 
2
 
/
 
2
 
 cells and contributes to
FN-stimulated signaling events (Sieg et al., 1998). How-
ever, the level of FN- and serum-stimulated extracellular
signal–regulated kinase (ERK)2 activation is lower in
FAK
 
2
 
/
 
2
 
 cells compared with FAK
 
1
 
/
 
1
 
 cells (Sieg et al.,
1998; Renshaw et al., 1999). FN stimulation of fibroblasts
promotes c-Jun NT kinase (JNK) kinase cascade activation
(Oktay et al., 1999) potentially through the phosphoryla-
tion of FAK-associated proteins such as p130
 
Cas
 
 (Dolfi et
al., 1998; Almeida et al., 2000) or through a complex of
paxillin-associated proteins (Igishi et al., 1999). FAK
 
2
 
/
 
2
 
cells do not generate signals leading to JNK activation af-
ter FN stimulation, and stable FAK reconstitution rescues
these signaling defects (Lebrun et al., 2000).
Pyk2 overexpression can potentiate FN-stimulated
ERK2 activation in FAK
 
2
 
/
 
2
 
 cells (Sieg et al., 1998), but
this does not efficiently promote cell migration (Sieg et al.,
1998). In contrast, FAK reexpression restores the charac-
teristic fibrillar shape of primary fibroblasts, promotes en-
hanced focal contact remodeling events (Ren et al., 2000),
and reestablishes normal migratory responses of FAK
 
2
 
/
 
2
 
cells (Sieg et al., 1998, 1999, 2000; Owen et al., 1999). Tran-
sient expression of various FAK mutants showed that
FAK kinase activity, the Tyr-397/SH2 binding site, and the
first proline-rich SH3 binding region in the FAK-CT do-
main were individually needed to promote FN-stimulated
FAK
 
2
 
/
 
2
 
 cell migration (Sieg et al., 1999).
To test the hypothesis that the perinuclear distribution
of Pyk2 in FAK
 
2
 
/
 
2
 
 cells may hinder it from functioning to
promote motility signals, Pyk2/FAK chimeras were con-
structed and evaluated for their ability to localize to focal
contacts and to enhance FAK
 
2
 
/
 
2
 
 cell migration. Here we
show that the Pyk2-NT and kinase domains can function-
ally substitute for FAK in rescuing the morphological, FN-
stimulated migratory, and FN-stimulated signaling defects
to ERK and JNK kinases when targeted to focal contact
sites by the FAK-CT domain in FAK
 
2
 
/
 
2
 
 cells. These stud-
ies highlight binding differences within the Pyk2 and
FAK-CT domains in making connections to focal contacts
and 
 
b
 
1-integrin signaling complexes. In addition, these
studies support the hypothesis that FAK functions to coor-
 
dinate the formation of migration-promoting signaling
complexes localized at focal contact sites.
 
Materials and Methods
 
Materials
 
FN was purchased from Sigma-Aldrich. Antibodies to the hemagglutinin
(HA) (mAb 16B12) and Myc (mAb 9E10) epitope tags were purchased
from Covance Research; mAbs to vinculin (clone hVIN-1), talin (clone
8d4), and to the flag epitope (clone M2) were purchased from Sigma-
Aldrich; and mAbs to paxillin (clone 349) and p130
 
Cas
 
 (clone 21) were
purchased from BD PharMingen/Transduction Labs. HA epitope mAb
(12CA5), and affinity-purified rabbit polyclonal antibodies to the Pyk2-
NT domain (# 5906), to the FAK-NT domain (# 5904), and to the FAK-
CT domain (# 5592) were used as described (Sieg et al., 1998). Purified an-
tibodies to the 
 
b
 
1-integrin cytoplasmic domain were a generous gift from
Martin Schwartz (The Scripps Research Institute). Site- and phospho-spe-
cific affinity-purified polyclonal antibodies to Pyk2 pTyr-402 and to Pyk2
pTyr-579 were generous gifts from Erik Schaefer (Biosource Interna-
tional, Camarillo, California). Polyclonal antibodies to JNK1/2 (sc-572)
and to ERK2 (c-14) were purchased from Santa Cruz Biotechnology, Inc.,
and antibodies to active phospho-JNK (pTPpY) were purchased from
Promega. mAb to ERK2 (B3B9) was obtained from M. Weber (Univer-
sity of Virginia, Charlottesville, VA) and an mAb to active phospho-ERK
(9105) was purchased from New England Biolabs, Inc. Human 293 Phoe-
nix-Eco packaging cells were obtained from Gary Nolan (Stanford Uni-
versity, Palo Alto, CA). The PD98059 inhibitor of the mitogen-activated
protein kinase (MEK) was purchased from Calbiochem.
 
Site-directed Mutagenesis and Cloning
 
Pyk2/FAK chimeras were created using QuikChange (Stratagene) site-
directed mutagenesis to introduce restriction sites in both Pyk2 and FAK.
Using a restriction site–modified Myc-tagged human Pyk2 cDNA template
(Sieg et al., 1998), unique ClaI and AflII sites were added at nucleotide po-
sitions 1225 and 2044, respectively, to the ATG start site. The introduction
of the AflII site changed Pyk2 residues Tyr-683 to Leu and Gln-684 to Arg
whereas the ClaI site addition did not change the coding sequence for Pyk2
residues Glu-404 and Ile-405. The exchange of the CT domain (residues
683–1009) of Pyk2 with the CT domain (residues 680–1052) of murine
FAK (Pyk2/FAK-CT) was accomplished by ligating a BamHI–AflII Pyk2
fragment into the same sites within a restriction site–modified FAK cDNA
template (Sieg et al., 1998). Pyk2/FAK-CT has an NT 6
 
3
 
-Myc tag, con-
tains the Pyk2 kinase domain, and has a CT 3
 
3
 
-HA tag. The exchange of
the NT domain (residues 1–405) of Pyk2 with the NT domain (residues
1–400) of FAK (FAK/Pyk2-CT) was accomplished ligating a ClaI–XbaI
Pyk2 fragment into the same sites of a FAK cDNA. A Myc tag was added
to FAK/Pyk2-CT by subcloning into pCS-Myc tag (Sieg et al., 1998). FAK/
Pyk2-CT has an NT 6
 
3
 
-Myc tag and contains the Pyk2 kinase do-
main. Both Pyk2/FAK-CT and FAK/Pyk2-CT were subcloned into the
pCDNA3.1 expression vector for transient expression studies. Pyk2/FAK-
CT (S-1034) was generated by subcloning an AflII–BamHI fragment from
S-1034 FAK-related nonkinase (FRNK) into the same sites within Pyk2/
FAK-CT. BamHI fragments from pCDNA3.1 Pyk2/FAK-CT or Pyk2/
FAK-CT (S-1034) were subcloned into the pRetro expression vector (In-
vitrogen) for stable expression studies in FAK
 
2
 
/
 
2
 
 cells.
 
Cells and DNA Constructs
 
Primary mouse fibroblasts were isolated from day 8 
 
fak
 
1
 
/
 
1
 
 or 
 
fak
 
2
 
/
 
2
 
 em-
bryos and carried mutations in the p53 gene introduced by crossing mice
heterozygous for the FAK and p53 alleles as described (Ilic et al., 1995).
Cells were maintained in DMEM supplemented with 10% FBS as de-
scribed (Sieg et al., 1998). Both FAK
 
2
 
/
 
2
 
 control cells and DA2 HA-tagged
FAK-reconstituted cells were selected for growth in hygromycin as de-
scribed (Sieg et al., 1999). Human 293T cells were cultured as described
(Schlaepfer et al., 1998). Mammalian expression vectors (in pCDNA) for
HA-tagged wild-type FAK, F-397 FAK, FAK S-1034, FRNK, FRNK S-1034,
and Myc-tagged Pyk2 were used as described (Sieg et al., 1998, 1999).
 
Transfection
 
Transient transfection of FAK
 
2
 
/
 
2
 
 or Pyk2/FAK-CT expressing cells was
performed using Lipofectamine Plus (GIBCO BRL) with 2.5 
 
m
 
g of the in-
dicated constructs exactly as described (Sieg et al., 1999). Stable expres- 
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99
 
sion of Pyk2/FAK-CT or Pyk2/FAK-CT (S-1034) in FAK
 
2
 
/
 
2
 
cells was ac-
complished by retroviral infection and puromycin selection (2–5 
 
m
 
g/ml).
In brief, 293 Phoenix-Eco packaging cells were transfected with pRetro
Pyk2/FAK-CT and the medium containing retrovirus was collected after
48 h. FAK
 
2
 
/
 
2
 
 cells (passage 14) were treated with 5 
 
m
 
g/ml polybrene and
infected for 24 h. Stable Pyk2/FAK-CT expression was detected in a sub-
set of the puromycin-resistant cell population. Clonal Pyk2/FAK-CT
(clones CA3 and CB4) or Pyk2/FAK-CT S-1034 (clones SE6 and SX4) ex-
pressing cells were obtained by FACS
 
®
 
 sorting of single cells into 96-well
plates followed by expansion. Transient transfection of human 293T cells
was performed by standard calcium phosphate methods as described
(Schlaepfer et al., 1998).
 
Haptotaxis Cell Migration Assays
 
Cells cotransfected with a pCDNA3-lacZ expression vector (2.5 
 
m
 
g) and
the construct of interest (2.5 
 
m
 
g) were used 36 h after transfection and se-
rum starvation (0.5% FBS, overnight). MilliCell chambers (8 
 
m
 
m pores;
Millipore) were coated on the underside with FN (10 
 
m
 
g/ml in DMEM for
transient transfection assays and 2 
 
m
 
g/ml for assays with stable cell lines)
for 2 h at room temperature. Membranes were washed with PBS to re-
move excess ligand and air dried (30 min). Cells were suspended by lim-
ited trypsin-EDTA treatment, washed by centrifugation and resuspension
in soybean trypsin inhibitor (0.25 mg/ml in DMEM), suspended in Migra-
tion Medium (DMEM with 0.5% BSA), and counted. 10
 
5
 
 cells in 0.3 ml
were added to each MilliCell chamber, and the units were placed into a
24-well dish containing 0.4 ml Migration Medium, and incubated for 3 h at
37
 
8
 
C. Transfected migratory cells were identified by 
 
b
 
-galactosidase
(
 
b
 
-gal) activity and counted; assays with stable cell lines were processed
by Crystal Violet staining as described (Sieg et al., 1999). Mean values
were obtained from three individual chambers for each experimental
point per assay. The PD98059 pharmacological MEK inhibitor (10–50
 
m
 
M) was added to suspended cells and included in the migration assay as
indicated. FN stimulation for signaling analyses was performed by replat-
ing of serum-starved cells (0.5% FBS for 18 h) onto FN-coated dishes
(2 
 
m
 
g/ml in PBS) in Migration Medium as described (Sieg et al., 1998).
 
In Vitro Kinase Assays
 
Immunoprecipitation (IP) in vitro kinase assays were performed with ly-
sates of cells plated onto FN-coated (10 
 
m
 
g/ml) dishes for 30 min as de-
scribed previously (Sieg et al., 1998). In brief, 10 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]ATP was
added to immunoisolated proteins and incubated at 37
 
8
 
C for 20 min in ki-
nase buffer (20 mM Hepes, pH 7.4, 10% glycerol, 10 mM MgCl
 
2
 
, and 150
mM NaCl). Labeled proteins were visualized by autoradiography after
SDS-PAGE. To measure ERK2 kinase activity, polyclonal ERK2 IPs
were made from 500 
 
m
 
g total cell lysate, washed in Triton Lysis buffer, fol-
lowed by HNTG buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 0.1% Tri-
ton X-100, 10% glycerol), and then in ERK2 kinase buffer (25 mM Hepes,
pH 7.4, 10 mM MgCl
 
2
 
). 2.5 
 
m
 
g of myelin basic protein (MBP) was added
to each IP as a substrate. Kinase reactions (
 
z
 
35 
 
m
 
l total vol) were initiated by
ATP addition (5 
 
m
 
l, final concentration 20 
 
m
 
M ATP, 10 
 
m
 
Ci/nmol [
 
g
 
-
 
32
 
P]ATP),
incubated at 32
 
8
 
C for 10 min, and stopped by the addition of 2
 
3
 
 SDS-
PAGE sample buffer. Transfection of 293T cells with a flag-tagged JNK-1
reporter and measurements of JNK in vitro kinase activity towards GST-
c-Jun were performed exactly as described (Almeida et al., 2000).
 
Immunofluorescence
 
Cells in Migration Medium (10
 
4
 
 cells/ml) were plated on FN-coated (10
 
m
 
g/ml) glass slides for 2 h and samples were fixed in 3.7% paraformalde-
hyde, permeabilized with ice-cold acetone for 10 min, and processed for
either vinculin, HA tag, Pyk2, or Myc tag indirect immunofluorescence
staining exactly as described (Sieg et al., 1999). Cells were viewed using an
Olympus BX60 epifluorescence microscope and photographed with
TMAX 400 film (Eastman Kodak Co.).
 
Immunoprecipitation and Immunoblotting
 
Cells were solubilized in a modified RIPA lysis buffer containing 1% Triton
X-100, 1% sodium deoxycholate, and 0.1% SDS as described (Schlaepfer et
al., 1998). For coimmunioprecipitation studies, cells on a 10-cm dish were
lysed with 500 
 
m
 
l RIPA buffer, scraped and collected, diluted with 500 
 
m
 
l
HNTG buffer, sheared by passage through a 22 gauge needle, and pre-
cleared by incubation with agarose beads. Cell lysates for the IPs contained
1–2 mg total cell protein, which varied due to cell density. Antibodies were
incubated with lysates for 2.5 h at 4
 
8
 
C and collected with either Protein A or
 
Protein G Plus (Oncogene Research Products) agarose beads. Antibody-
complexed proteins were washed at 4
 
8
 
C with Triton-only lysis buffer, fol-
lowed by washes with HNTG buffer, and analyzed by SDS-PAGE. Immu-
noblotting of proteins transferred to polyvinylidene difluoride membranes
(Millipore) was performed with either 1 
 
m
 
g/ml monoclonal or a 1:1,000 dilu-
tion of polyclonal antibodies (in TBS containing 2% BSA and 0.05%
Tween 20) for 2 h at room temperature and visualized by enhanced chemi-
luminescent detection methods. Sequential reprobing of membranes was
performed as described (Schlaepfer et al., 1998).
 
Results
 
Pyk2/FAK Chimeras
 
Since FAK but not Pyk2 is capable of rescuing the migra-
tion defects of FAK
 
2
 
/
 
2
 
 cells (Owen et al., 1999; Sieg et al.,
1999), chimeric Pyk2/FAK proteins were created to deter-
mine whether the kinase domains of these PTKs were inter-
changeable and whether functional differences existed in
the NT or CT domains of FAK and Pyk2, respectively. The
Pyk2/FAK-CT chimera consists of the FAK-CT domain
(residues 680 to end) added to the NT and kinase domains
of Pyk2 (Fig. 1 A). The FAK/Pyk2-CT chimera consists of
the FAK-NT domain (residues 1–400) added to the kinase
and CT domains of Pyk2. Transient expression of the chi-
meric proteins in FAK
 
2
 
/
 
2
 
 cells showed that FAK/Pyk2-CT
and Pyk2/FAK-CT exhibited equivalent in vitro 
 
32
 
P auto-
phosphorylation activity compared with exogenously ex-
pressed FAK and Pyk2 (Fig. 1 B).
FAK
 
–/–
 
 cells form an increased number of focal contacts,
and the enhanced stability of these contacts is associated
with motility defects (Sieg et al., 1999; Ren et al., 2000).
Expression of Myc-tagged Pyk2 exhibits a perinuclear dis-
tribution in FAK
 
2
 
/
 
2
 
 cells and does not significantly colo-
calize with the focal contact–associated protein vinculin
(Fig. 2 A). This distribution of exogenous Pyk2 is similar
to endogenous Pyk2 in FAK
 
2
 
/
 
2
 
 cells and contrasts to the
focal contact localization of FAK when expressed in
FAK
 
2
 
/
 
2
 
 cells (Sieg et al., 1998, 1999). Interestingly, FAK/
Pyk2-CT exhibited a perinuclear distribution whereas
Pyk2/FAK-CT localized to FAK
 
2
 
/
 
2
 
 focal contact sites
(Fig. 2 A). Even though previous studies have shown that
exogenous expression of the isolated Pyk2-CT domain lo-
calized to focal contacts in chicken embryo fibroblasts
(Schaller and Sasaki, 1997), our results demonstrate that
the Pyk2-CT and FAK-CT domains are not equivalent.
Namely, the FAK-CT domain promotes the redistribution
of the Pyk2-NT and kinase domains to focal contacts in
FAK
 
2
 
/
 
2
 
 cells whereas the Pyk2-CT domain does not func-
tion in this manner.
 
Pyk2/FAK-CT Promotes FN-stimulated FAK
 
2
 
/
 
2
 
Cell Migration
 
To test whether Pyk2/FAK-CT can rescue FAK
 
2
 
/
 
2
 
 cell
motility defects, Boyden chamber haptotaxis cell migra-
tion assays were conducted with immobilized FN as the
stimulus. FAK/Pyk2-CT expression and Pyk2 overexpres-
sion enhanced FAK
 
2
 
/2 cell motility approximately three-
fold over cells transfected with vector alone (Fig. 2 B).
These motility values are consistent with those previously
published for Pyk2 overexpression in FAK2/2 cells (Sieg
et al., 1998). Significantly, cells transfected with Pyk2/
FAK-CT exhibited an z10-fold increase in FN-stimulated
migration over FAK2/2 cells transfected with vector aloneThe Journal of Cell Biology, Volume 152, 2001 100
(Fig. 2 B). FAK2/2 cell migration enhanced by Pyk2/FAK-
CT is similar to the level promoted by transient FAK over-
expression (Sieg et al., 1998, 1999). Direct blotting analyses
of excess cells not used in the migration assay showed that
Pyk2, FAK/Pyk2-CT, and Pyk2/FAK-CT were equiva-
lently overexpressed in the transiently transfected FAK2/2
cells (Fig. 2 B). Expression of these constructs did not af-
fect endogenous levels of b1-integrin expression (Fig. 2
B), and the level of overexpression was z10-fold greater
than endogenous Pyk2 (data not shown). These results
show a direct correlation between Pyk2/FAK-CT focal
contact localization and the enhancement of FN-stimu-
lated cell migration. In addition, these results demonstrate
that the Pyk2-NT and kinase domains can functionally
substitute for FAK in promoting FN-stimulated cell mi-
gration if targeted to focal contact sites.
Figure 1. Creation of Pyk2 and FAK chimeric proteins. (A)
Schematic representation of HA-FAK, Myc-Pyk2, Pyk2/FAK-
CT, and FAK/Pyk2-CT. Pyk2/FAK-CT consists of Pyk2 residues
1–682 including the Pyk2 kinase domain and FAK residues 680–
1052. FAK/Pyk2-CT consists of FAK residues 1–400 including
the intact Src SH2 binding site surrounding FAK Tyr-397 and
Pyk2 residues 405–1009 encompassing the Pyk2 kinase and CT
domains. The inclusion of either six repeated Myc tags at the NT
domain or three repeated HA tags at the CT domain is indicated
for each construct. (B) Analysis of FN-stimulated 32P in vitro ki-
nase activity as measured in IPs to the transiently expressed
epitope-tagged proteins. Immunoprecipitated proteins were
transferred to PVDF membranes and visualized by autoradiogra-
phy, followed by HA and Myc tag blotting. PBS, paxillin binding
sequence.
Figure 2. Transient expression of Pyk2/FAK-CT localizes to focal
contacts and promotes FN-stimulated FAK2/2 cell motility. (A)
FAK2/2 cells transiently transfected with either pCDNA3 control
vector, Pyk2, Pyk2/FAK-CT, or FAK/Pyk2-CT were grown on FN-
coated glass slides overnight and stained with an antibody to vincu-
lin or to the Myc epitope tag. Arrows indicate transfected cells. (B)
FAK2/2 cells were transiently cotransfected with 2.5 mg pCDNA3.1-
lacZ and either control vector, Pyk2, FAK/Pyk2-CT, or Pyk2/FAK-
CT (2.5 mg each in pCDNA3.1) and were analyzed for FN-stimu-
lated (10 mg/ml) haptotaxis cell migration (3 h). Transfected migratory
cells were identified by b-gal staining and counted. Exogenous pro-
tein expression was verified in the excess cells not used in the migra-
tion assay by Myc tag blotting. Relative fold induction of migration
was calculated by normalizing transfection-induced migration to the
pCDNA3.1 control transfected FAK2/2 cells. Data represent the
mean 6 SD of four independent experiments. Bar, z20 mM.Klingbeil et al. Analyses of Pyk2/FAK Chimeras in FAK-null Cells 101
Stable Pyk2/FAK-CT Expression Promotes Changes in 
FAK2/2 Cell Morphology
To better evaluate Pyk2/FAK-CT function without over-
expression, retroviral-mediated infection and puromycin
selection were employed to achieve stable Pyk2/FAK-CT
expression in FAK2/2 cells. In addition, a point mutation
(S-1034) was introduced in the FAK-CT domain of Pyk2/
FAK-CT which disrupts paxillin binding to FAK in vitro
and in vivo (Tachibana et al., 1995; Sieg et al., 1999), and
this construct was also stably expressed in FAK2/2 cells.
Puromycin-resistant pools of Pyk2/FAK-CT infected cells
displayed both rounded and spread morphologies (data
not shown). Immunofluorescence staining showed that
Pyk2/FAK-CT expression was detected in a subset of the
total population (data not shown) and therefore, clonal
cell lines were isolated for both Pyk2/FAK-CT and Pyk2/
FAK-CT S-1034 expressing cells.
To compare the stable expression levels of the various
constructs, equal total protein from FAK2/2, FAK1/1,
DA2 (FAK reconstituted), Pyk2/FAK-CT expressing
(clones CA3 and CB4), or Pyk2/FAK-CT S-1034 (clones
SE6 and SX4) was resolved by SDS-PAGE and analyzed
by blotting with antibodies either to the FAK-CT domain
or the Myc and HA tags on the exogenously expressed
proteins (Fig. 3 A). By comparisons of the FAK blot signal
obtained between FAK1/1 and DA2 cells, stable HA-
FAK expression is at z10% of endogenous FAK levels
whereas p130Cas and the b1-integrin were equivalently ex-
pressed in these cells (Fig. 3 A, lanes 2 and 3). By compar-
isons of the FAK, Myc, and HA tag blots of the cell ly-
sates, Pyk2/FAK-CT expression in the CA3 cells was at
z30% the level of FAK in FAK1/1 cells, whereas Pyk2/
FAK-CT in the CB4 cells was expressed equivalently to
FAK in FAK1/1 cells (Fig. 3 A, lanes 4 and 5). Similar
Pyk2/FAK-CT S-1034 expression levels were found in the
lysates of SE6 and SX4 cells compared with Pyk2/FAK-
CT in the CA3 and CB4 cells, respectively. Importantly,
these results show that none of the exogenously expressed
constructs were overexpressed compared with the level of
endogenous FAK expression in FAK1/1 cells.
The low levels of stable HA-FAK expression in the
DA2 cells are sufficient to promote a reversal of the
rounded FAK2/2 fibroblast morphology to a normal fibro-
blast shape (Sieg et al., 1999). Cell shape differences be-
tween FAK2/2 and FAK-reconstituted cells are most evi-
dent on FN replating (Fig. 3 B). Whereas no differences in
cell attachment to FN were observed (data not shown),
FAK2/2 cells remain rounded while FAK-reconstituted
DA2 cells were well spread after 2 h on FN (Fig. 3 B). By
indirect immunofluorescence staining, endogenous Pyk2
was detected in a punctate perinuclear distribution in the
most spread FAK2/2 cells, whereas HA-FAK was strongly
localized to focal contact regions and cell projections in
DA2 cells (Fig. 3 B). Stable Pyk2/FAK-CT expression in
CA3 and CB4 cells promoted a normal polarized fibro-
blast morphology and Pyk2/FAK-CT was strongly local-
ized to peripheral focal contact sites and leading projec-
tions (Fig. 3 B). In contrast, Pyk2/FAK-CT S-1034
expression in SX4 cells at levels equivalent to Pyk2/FAK-
CT in CB4 cells (Fig. 3 A) enhanced cell spreading com-
pared with FAK2/2 cells, but did not result in a polarized
cell morphology (Fig. 3 B). Pyk2/FAK-CT S-1034 was pri-
marily perinuclear distributed in SX4 cells and not signifi-
cantly localized to perimeter focal contacts that were visu-
alized by vinculin staining of SX4 cells (Fig. 3 B). Since the
S-1034 mutation in the FAK-CT domain disrupts paxillin
binding (Tachibana et al., 1995; Sieg et al., 1999), these re-
sults support the conclusion that FAK-CT interactions
with paxillin play an important role in FAK localization to
focal contact sites.
Stable Expression of Pyk2/FAK-CT but Not the S-1034 
Mutant Rescues FAK2/2 Haptotactic Motility Defects
To determine whether stable Pyk2/FAK-CT expression
and localization to focal contact sites also enhanced FN-
stimulated cell migration, comparisons were made be-
tween FAK2/2, FAK1/1, DA2, CA3, CB4, SE6, and SX4
cells in modified Boyden chamber motility assays (Fig. 4).
When assays were performed only in the presence of 0.5%
BSA, only low levels of random cell motility were ob-
served for all cells. When stimulated by immobilized FN
on the underside of the Boyden chamber membrane,
FAK1/1, DA2, CA3, and CB4 cells all showed a three to
four fold increase in cell motility compared with the low
level of FN-stimulated FAK2/2 cell migration (Fig. 4).
These fold differences are less than those stimulated by ei-
ther FAK or Pyk2/FAK-CT transient overexpression (Fig.
2 B), but are identical to those previously measured for
comparisons between FAK2/2 and FAK-reconstituted
clonal cell lines (Sieg et al., 1999). Importantly, although
HA-FAK expression in the DA2 cells and Pyk2/FAK-CT
expression in the CA3 cells are less than FAK expression
in FAK1/1 cells (Fig. 3 A), both HA-FAK and Pyk2/FAK-
CT strongly localized to focal contacts (Fig. 3 B) and fully
rescued FAK2/2 cell haptotactic motility defects (Fig. 4).
Curiously, previous studies showed that transient FAK
S-1034 overexpression in FAK2/2 cells could localize to fo-
cal contacts and partially function to enhance FN-stimu-
lated cell migration (Sieg et al., 1999). Strikingly, introduc-
tion of this S-1034 mutation in Pyk2/FAK-CT resulted in
the disruption of Pyk2/FAK-CT focal contact localization
(Fig. 3 B) and the inhibition of Pyk2/FAK-CT function in
promoting FN-stimulated cell motility as analyzed in SE6
and SX4 cells (Fig. 4). These results highlight complica-
tions in the interpretation of results obtained from overex-
pression studies. Namely, results from the stable cell lines
support the conclusion that the S-1034 mutation in the
FAK-CT domain disrupts binding interactions needed for
high affinity focal contact targeting. However, if expressed
at high enough levels, FAK S-1034 could be driven to focal
contacts by low affinity interactions and could partially
function in motility assays (Sieg et al., 1999).
Paxillin Binding Is Necessary but Not Sufficient to 
Mediate Pyk2/FAK-CT Linkage to b1-Integrins
The inability of stable Pyk2/FAK-CT S-1034 expression to
promote FN-stimulated motility supports the importance
of paxillin binding for proper focal contact localization
and Pyk2/FAK-CT function. Since paxillin has been
shown to bind peptides derived from the b1-integrin cyto-
plasmic domain (Schaller et al., 1995), coimmunoprecipi-
tation experiments were performed to determine whether
paxillin binding was sufficient to promote b1-integrin as-
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5). FAK and Pyk2/FAK-CT associated with a b1-integrin–
containing complex (Fig. 5, lanes 3 and 5), whereas FAK
S-1034, which does not bind paxillin, did not detectably as-
sociate with the b1-integrin (Fig. 5, lane 6). Interestingly,
Myc-tagged Pyk2 associated with paxillin, but did not de-
tectably associate with a b1-integrin–containing complex
(Fig. 5, lane 2). All constructs were equivalently active, as
they associated with p130Cas which binds to a conserved
proline-rich motif located in the FAK and Pyk2-CT do-
mains (Fig. 5). Importantly, the FAK S-1034 results sup-
port the conclusion that paxillin binding is necessary for
b1-integrin association. However, the fact that Pyk2 asso-
ciates with paxillin but does not localize to focal contacts
(Fig. 2 A) or promote FN-stimulated cell migration (Fig. 2
B) shows that singular paxillin binding to the Pyk2-CT do-
main is not sufficient to mediate a complex formation with
the b1-integrin. Only constructs containing the FAK-CT
domain localized to focal contacts in FAK2/2 cells and as-
sociated with the b1-integrin. These results do not support
the proposed role of the FAK-NT domain in mediating ei-
ther direct or functional interactions with the b1-integrin
cytoplasmic domain (Schaller et al., 1995).
Another potential intermediary protein is the b1-inte-
grin-associated structural protein, talin (Chen et al., 1995;
Calderwood et al., 1999). Co-IP experiments showed
that  talin associated with Pyk2/FAK-CT, FAK, and FAK
S-1034, but not with Pyk2 (Fig. 5). Only those constructs
containing the FAK-CT domain associated with talin, and
these results support previous conclusions showing the dif-
ferential binding of talin to the FAK-CT but not Pyk2-CT
domains (Zheng et al., 1998). However, the fact that FAK
S-1034 bound strongly to talin but did not associate with a
b1-integrin–containing complex (Fig. 5, lane 6) shows that
singular talin binding to the FAK-CT domain also is not
sufficient to promote a linkage to the b1-integrin. Whereas
it is possible that a specific, yet unknown protein binds to
the FAK-CT domain to facilitate a linkage to the b1-inte-
grin, it is also plausible that the combined binding of pro-
teins such as paxillin and talin to the FAK-CT domain fa-
cilitates b1-integrin association, high affinity focal contact
localization, and the ability of FAK or Pyk2/FAK-CT to
promote FN-stimulated cell motility.
Figure 3. Stable Pyk2/FAK-CT expression promotes
fibrillar morphology of FAK2/2 cells. (A) Equal total
protein from WCLs of FAK2/2, FAK1/1, HA-FAK
reconstituted (DA2), Pyk2/FAK-CT reconstituted
(clones CA3 and CB4), or Pyk2/FAK-CT S-1034 re-
constituted (clones SE6 and SX4) were resolved by
SDS-PAGE and sequentially blotted with antibodies
to either the FAK-CT domain, Myc tag, HA tag,
p130Cas, or to the cytoplasmic domain of the b1-inte-
grin. Panels are a compilation from two gels. The po-
sitions of FAK, HA-FAK, Pyk2/FAK-CT, and a non-
specific band are indicated in the FAK-CT blot. (B)
FAK2/2, DA2, CA3, CB4, and SX4 cells were plated
onto FN-coated (10 mg/ml) glass slides for 2 h in the
absence of serum and stained with either affinity-
purified antibodies to Pyk2, an mAb to the HA tag,
or an mAb to vinculin as indicated (inset). Arrows in-
dicate focal contact staining. Bar, z20 mM.Klingbeil et al. Analyses of Pyk2/FAK Chimeras in FAK-null Cells 103
Kinase Domain Activation of Pyk2/FAK-CT but Not 
the S-1034 Mutant after FN Stimulation of Cells
Previous studies have shown that FAK kinase activity is re-
quired to promote FN-stimulated motility of FAK2/2 cells
(Sieg et al., 1998, 1999) and that FAK targeting to focal con-
tacts is an important factor promoting its activation (Shen
and Schaller, 1999). To determine whether the Pyk2 kinase
domain exhibits integrin-specific activation when stably ex-
pressed and targeted to focal contacts in CA3 and CB4
cells, signaling comparisons were performed with FAK2/2,
DA2, CA3, CB4, SE6, and SX4 cells (Fig. 6). Antibodies di-
rected to the Pyk2-NT domain and to the FAK-CT domain
were combined to immunoprecipitate both endogenous
Pyk2 or exogenously expressed HA-FAK in DA2 cells,
Pyk2/FAK-CT in CA3 and CB4 cells, or Pyk2/FAK-CT
S-1034 in SE6 and SX4 cells. Upon FN stimulation, en-
hanced tyrosine phosphorylation of Pyk2 in FAK2/2 cells
(Fig. 6, lane 1), HA-FAK (Fig. 6, lane 2), or Pyk2/FAK-CT
(Fig. 6, lanes 3 and 4) occurred compared with no detect-
able tyrosine phosphorylation of these proteins in sus-
pended cells (data not shown).
Interestingly, Pyk2/FAK-CT S-1034 was not detectably
tyrosine phosphorylated in SE6 cells, whereas at higher
levels of expression in SX4 cells, Pyk2/FAK-CT S-1034
was strongly tyrosine phosphorylated after FN stimulation
(Fig. 6, lanes 5 and 6). It is known that FN-stimulated
phosphorylation of FAK Tyr-397 is a key event in promot-
ing Src-family PTK SH2-mediated binding, and FAK
phosphorylation within the kinase domain activation loop
at Tyr-576 is required for maximal kinase domain activity
(Ruest et al., 2000). In Pyk2, these sites are conserved at
Tyr-402 and Tyr-579, respectively. Reprobing the IPs with
site and phospho-specific antibodies to Pyk2 pY402 and
Pyk2 pY579 revealed that Tyr-402 was phosphorylated in
both Pyk2/FAK-CT and Pyk2/FAK-CT S-1034 (Fig. 6).
Significantly, Tyr-579 within the Pyk2 kinase domain was
phosphorylated only in Pyk2/FAK-CT and not in Pyk2/
FAK-CT S-1034 (Fig. 6, lanes 3–6). These results support
the hypothesis that FN stimulation of cells promotes Pyk2/
FAK-CT kinase domain activation only if it is localized to
focal contact sites.
Both Pyk2/FAK-CT S-1034 and endogenous Pyk2 ex-
hibited increased phosphorylation at Tyr-402 but not Tyr-
579 after FN stimulation of SX4 and FAK–/– cells, respec-
tively (Fig. 6, lanes 1 and 6). Previous studies have shown
that FN stimulation of FAK2/2 cells promotes the activa-
tion of Src-family PTKs and results in the transphosphory-
lation but not direct activation of Pyk2 (Sieg et al., 1998).
The fact that Pyk2/FAK-CT S-1034 exhibits a perinuclear
distribution (Fig. 3 B) and is not detectably phosphory-
lated at Tyr-579 within the kinase domain (Fig. 6) shows
that Pyk2/FAK-CT S-1034 is not appropriately activated
after FN stimulation of the SX4 cells. These results dem-
onstrate the importance of functional FAK-CT–mediated
localization to sites of integrin receptor clustering as a re-
quired event in promoting Pyk2/FAK-CT kinase domain
activation after FN stimulation of cells.
Figure 4. FAK-CT but not FAK-CT S-1034 mediated targeting
of the Pyk2-NT and kinase domains to focal contacts rescues
FAK2/2 FN-stimulated motility defects. Boyden chamber FN-
stimulated haptotaxis migration assays (3 h) were performed
with equal numbers of FAK2/2, FAK1/1, DA2, CA3, CB4, SE6,
and SX4 fibroblasts. Migratory cells on the membrane underside
were stained with Crystal Violet and the dye absorbence was
quantified at 600 nm. Data represent the mean 6 SD of seven in-
dependent experiments.
Figure 5. FAK-CT domain–mediated connections to a b1-inte-
grin–containing complex. FAK2/2 cells were transfected with ex-
pression vectors for either Myc-Pyk2, Myc–Pyk2/FAK-CT (with
HA tag on CT domain), HA-FAK, HA-FAK S-1034, and the ex-
ogenous proteins were isolated with antibodies to either the Myc
(lanes 1–3) or HA epitope tags (lanes 4–6). Two sets of IPs were
sequentially analyzed for associated proteins by anti–b1-integrin,
antitalin, anti-p130Cas, and antipaxillin blotting. Control IPs
showing nonspecific protein association were performed with
control vector (pCDNA) transfected cells using either Myc tag
(lane 1) or HA tag (lane 4) antibodies. Combined blotting of
WCLs on the adjacent gel lane was used to verify specific protein
immunoreactivity (1/20 of total cell lysate) and represents an
equal chemiluminescent exposure to the IP lanes. The trans-
fected proteins were detected by either Myc or HA tag blotting
of the IPs.The Journal of Cell Biology, Volume 152, 2001 104
FAK and Pyk2/FAK-CT Enhance the Extent and 
Duration of FN-stimulated ERK2 Activation Required 
for Haptotactic Motility
FAK binds to several different signaling proteins via SH2-
and SH3-mediated interactions and connections to Src-
family PTKs (Sieg et al., 1999), p130Cas (Cary et al., 1998;
Gu et al., 1999), Shc (Schlaepfer et al., 1998), the p85 sub-
unit of phosphatidylinositol 39-kinase (Reiske et al., 1999),
Grb7 (Han and Guan, 1999), SHP-2 (Manes et al., 1999),
phospholipase Cg-1 (Zhang et al., 1999), paxillin (Richard-
son et al., 1997), or the Rho GTPase activating protein
Graf (Taylor et al., 1999) could potentially link FAK to
promigratory signaling pathways. Since so many different
signaling proteins interact with FAK and have been pro-
posed to mediate cell migration signaling events, no clear
model has emerged on how FAK functions to promote cell
migration. To visualize potential signaling events through
which FAK and Pyk2/FAK-CT function to promote FN-
stimulated haptotactic cell motility, phosphotyrosine blot-
ting analyses were performed on whole cell lysates (WCLs)
from FN-stimulated FAK2/2, DA2, CA3, CB4, SE6, and
SX4 cells (Fig. 7 A). Consistent with the IP results in Fig. 6,
some of the major phosphotyrosine (P.Tyr)-containing
proteins visualized were Pyk2, HA-FAK, and Pyk2/FAK-
CT as indicated (Fig. 7 A). In FAK2/2 cells, Pyk2 and
p130Cas within the 116–130-kD size range as well as p52Shc
are tyrosine phosphorylated after FN stimulation (Sieg et
al., 1998). The increased FN-stimulated tyrosine phosphor-
ylation of p52Shc as well as unidentified proteins at z44,
z170, and z250 kD were visualized in lysates of DA2,
CA3, and CB4 cells compared with FAK2/2 cells (Fig. 7 A,
lanes 2–4). Previous studies have shown that both FAK
and Src-family PTKs can phosphorylate Shc after FN stim-
ulation of cells and that this is a major signaling pathway
promoting FN-stimulated ERK2 activation (Wary et al.,
1996; Schlaepfer et al., 1997, 1998).
To determine whether stable FAK or Pyk2/FAK-CT ex-
pression enhanced FN-stimulated ERK activation, lysates
from FN-stimulated cells were blotted using phospho-spe-
cific antibodies that recognize activated ERK kinases (Fig.
7 B). Low levels of active ERK were detected in FN-stim-
ulated FAK2/2 cells, whereas elevated levels of active
ERK were detected after FN stimulation of DA2, CA3,
and CB4 cells (Fig. 7 B). Reprobing of this blot showed
equal ERK2 expression in all samples (Fig. 7 B). Interest-
ingly, an intermediate level of active ERK was detected af-
ter FN stimulation of SX4 cells compared with FAK2/2
and DA2 cells (Fig. 7 B, lane 6). These findings are consis-
tent with FAK and Pyk2/FAK-CT functioning to promote
elevated ERK2 activation in DA2, CA3, and CB4 cells
and the partial ability of tyrosine-phosphorylated Pyk2/
FAK-CT S-1034 to enhance signaling in SX4 cells.
Since these differences in FN-stimulated ERK activa-
tion were analyzed only at one time point, lysates from
FAK2/2, DA2, and CA3 cells were analyzed for ERK2 ac-
tivation at various times (10–180 min) after FN replating
(Fig. 7 C). By blotting with an mAb to ERK2 that recog-
nizes both the unphosphorylated as well as activated
ERK2 (ERK2-P) which migrates slower in high percent-
age gels, maximal ERK2 activation occurred between 10
and 20 min in FAK2/2 cells (Fig. 7 C, lanes 3 and 4).
Whereas low levels of ERK2 activation occurred in sus-
pended DA2 and CA3 cells (Fig. 7 C, lane 2), maximal
FN-stimulated ERK2 activation was detected between 10
and 20 min in DA2 cells and between 10 and 30 min in
CA3 cells. Notably, both the extent and duration of FN-
stimulated ERK2 activation were increased in DA2 and
CA3 cells (10 to .180 min) compared with the time course
of ERK2 activation (10–90 min) in FAK2/2 cells (Fig. 7
C). The FN-stimulated ERK2 activation time course in
DA2 and CA3 cells is similar to that previously measured
in FN-stimulated NIH3T3 fibroblasts (Schlaepfer et al.,
1998). Importantly, time course analyses with SX4 cells
showed that Pyk2/FAK-CT S-1034 expression moderately
enhanced FN-stimulated ERK2 activation between 10 and
20 min, but did not affect the duration of ERK2 activation
compared with FAK2/2 cells (Fig. 7 C). These results show
that focal contact targeting of Pyk2/FAK-CT in CA3 cells
was required to promote maximal FN-stimulated ERK2
activation to the same extent as FAK.
To determine whether ERK2 activation was a required
component for FAK-mediated haptotactic cell motility,
Figure 6. Differential FN-stimulated Pyk2/FAK-CT and Pyk2/
FAK-CT S-1034 tyrosine phosphorylation. 2 3 106 FAK2/2,
DA2, CA3, CB4, SE6, or SX4 cells were plated on FN-coated
dishes (2 mg/ml) for 30 min and a combination of affinity-purified
antibodies to the FAK-CT or Pyk2–NT domain (2.5 mg each)
were used to isolate both endogenous Pyk2 and the stably ex-
pressed HA-FAK or Pyk2/FAK-CT proteins. IPs were resolved
by SDS-PAGE and sequentially blotted with antibodies to P.Tyr,
phospho-specific antibodies to either the Pyk2 pY402 or pY579
phosphorylation sites, to the Myc tag, or with an mAb to Pyk2 as
indicated. Panels are a compilation from two gels and the migra-
tion of Pyk2/FAK-CT, HA–FAK, or Pyk2 is indicated.Klingbeil et al. Analyses of Pyk2/FAK Chimeras in FAK-null Cells 105
Boyden chamber motility assays were performed in the
presence of PD98059 MEK inhibitor (Fig. 7 D). High num-
bers of DA2 cells migrated to the immobilized FN stimulus
compared with low levels of random cell migration in the
presence of BSA only. Treatment of the DA2 cells with
the PD98059 inhibitor revealed a dose-dependent inhibi-
tion of FN-stimulated DA2 cell motility (Fig. 7 D). Inhibi-
tion of DA2 cell motility was .60% at 50 mM PD98058
and control FN replating assays showed a corresponding
inhibition of FN-stimulated ERK2 activation at this con-
centration but no affect on cell attachment to FN (data not
shown). Similar findings were obtained with PD98059
treatment of CA3 cells (data not shown). Additional mi-
gration analyses using a pharmacological inhibitor to the
p38 kinase (SB203580) at similar concentrations did not
reveal significant inhibitory effects on DA2 haptotactic
migration (data not shown). These results show that acti-
vation of the ERK2 pathway positively contributes to hap-
totactic cell migration responses.
Pyk2/FAK-CT also Rescues FAK2/2 Cell Defects in 
FN-stimulated JNK Activation
Previous studies have shown that transient Pyk2 overex-
pression in FAK2/2 cells enhanced FN-stimulated ERK2
activation at 20 min to the same extent as FAK, but Pyk2
overexpression did not efficiently promote FAK2/2 hapto-
tactic motility (Sieg et al., 1998). Since transient overex-
pression of activated versions of either the Raf or MEK1
kinases also did not efficiently function to enhance FAK2/2
haptotactic motility (data not shown), we conclude from
the inhibitory PD98059 results (Fig. 7 D) that FAK-medi-
ated ERK2 activation is necessary but not sufficient to pro-
mote haptotactic motility. Another FN-stimulated signal-
ing pathway connected to FAK is the activation of JNK
Figure 7. Stable FAK and Pyk2/FAK-CT expression enhance the extent and duration of FN-stimulated ERK2 activation required for
cell motility. (A) Lysates from FN-stimulated cells were prepared as described in the legend to Fig. 6, and 50 mg of total cell protein/lane
was resolved by SDS-PAGE and analyzed by anti-P.Tyr blotting. (B) Lysates (50 mg) from the indicated FN-stimulated cells were blot-
ted with an mAb to activated and phosphorylated ERK1/ERK2 and then reprobed with an mAb to ERK2. (C) Lysates from either
FAK2/2, DA2, CA3, or SX4 cells were prepared from either serum-starved, suspended, or cells replated onto FN-coated (10 mg/ml)
dishes for the times indicated. Proteins were resolved on a 15% SDS-PAGE gel and analyzed by mAb ERK2 blotting. The slower mi-
grating form of ERK2 represents phosphorylated and active ERK2 (ERK2-(P)). (D) Serum-starved DA2 cells, pretreated in suspen-
sion with the indicated concentrations of PD98059 for 30 min, were employed in Boyden chamber haptotactic migration assays using
immobilized FN or BSA as stimulus. PD98059 was added to the lower chambers and after 3 h, cells on the lower side of the membrane
were fixed and stained, and the eluted dye was quantified by absorbence. Bars represent the means from two separate experiments.The Journal of Cell Biology, Volume 152, 2001 106
(Oktay et al., 1999; Almeida et al., 2000). FN stimulation of
FAK2/2 cells does not result in detectable JNK activation
and stable FAK reexpression rescues this defect (Lebrun
et al., 2000). By analyzing lysates from FN-stimulated
FAK2/2, DA2, CA3, CB4, SE6, and SX4 cells using phos-
pho-specific antibodies that recognize activated JNK ki-
nases, Pyk2/FAK-CT expression in CA3 and CB4 cells pro-
moted FN-stimulated JNK-1 activation equally as well as
FAK in DA2 cells (Fig. 8 A, lanes 2–4). Notably, whereas
tyrosine-phosphorylated Pyk2/FAK-CT S-1034 in SX4 cells
functioned to moderately enhance FN-stimulated ERK2
activation (Fig. 7, B and C), Pyk2/FAK-CT S-1034 expres-
sion did not detectably promote FN-stimulated JNK-1 acti-
vation in SE6 and SX4 cells (Fig. 8 A, lanes 5 and 6). These
results support the hypothesis that the focal contact local-
ization of FAK or Pyk2/FAK-CT is required to generate
FN-stimulated signaling events leading to JNK activation.
FRNK but Not FRNK S-1034 Expression Inhibits
FN-stimulated Signaling and Pyk2/FAK-CT Function 
in Promoting Haptotactic Motility
Previous studies have shown that expression of the FAK-
CT domain (also termed FRNK) expression promotes the
displacement of FAK from focal contact sites (Richardson
et al., 1997), dephosphorylation of FAK at Tyr-397 (Sieg
et al., 1999), and inhibition of FAK-mediated cell motility
(Gilmore and Romer, 1996; Richardson et al., 1997; Sieg et
al., 1999). To add support to the conclusion that FAK-CT–
mediated localization of Pyk2/FAK-CT to focal contacts
was required for cell migration, FRNK expression was
tested as a competitive inhibitor of FAK (Figs. 8 B and 9
A) or Pyk2/FAK-CT function (Fig. 9 B). To analyze
FRNK effects on FN-stimulated JNK activation, human
293T cells were transiently transfected with a flag-tagged
JNK-1 reporter along with FRNK or FRNK S-1034 (Fig. 8
B). Flag-tagged JNK-1 exhibited elevated in vitro kinase
activity toward GST-c-Jun in lysates from FN-stimulated
compared with lysates from suspended cells. Significantly,
coexpression of FRNK but not FRNK S-1034 inhibited the
activation of JNK-1 after FN stimulation of cells (Fig. 8 B).
Signaling analyses were also performed to determine
the effect of FRNK expression on FN-stimulated ERK2
activation (Fig. 9 A). Transient overexpression of FAK
but not F-397 FAK enhanced the activation of a flag-
tagged ERK2 reporter construct approximately three- to
fourfold after FN stimulation compared with control
transfected human 293T cells (Fig. 9 A). Integrin receptor
engagement was required as FAK overexpression had no
effect in transfected and suspended cells (Fig. 9 A), and
these results are consistent with studies showing that FN-
stimulated FAK phosphorylation at Tyr-397 is required
for FAK signaling functions (Schlaepfer and Hunter,
1997). Cotransfection of FRNK with FAK inhibited both
FN-stimulated FAK tyrosine phosphorylation and ERK2
activation (Fig. 9 A). Both FRNK and F-397 FAK overex-
pression resulted in z50% reduction in FN-stimulated
ERK2 activity compared with control transfected cells
(Fig. 9 A), consistent with similar assays performed in
NIH3T3 fibroblasts (Zhao et al., 1998).
To determine if FRNK expression could specifically in-
hibit Pyk2/FAK-CT function in promoting FAK2/2 hapto-
tactic motility, FRNK or S-1034 FRNK was transiently ex-
pressed along with a lacZ reporter in CA3 cells (Fig. 9 B).
Indeed, FRNK expression potently inhibited haptotaxis of
CA3 cells without affecting the expression level of Pyk2/
FAK-CT. Control FRNK S-1034 expression did not affect
FN-stimulated CA3 cell motility responses (Fig. 9 B). Our
combined results show the importance of FAK or Pyk2/
FAK-CT localization to focal contact sites for the genera-
tion of either distinct (JNK activation) or multiple signals
(ERK plus JNK activation) after FN stimulation of cells.
FRNK expression specifically inhibits FN-stimulated signal-
ing events promoting ERK2 and JNK activation and is a po-
tent inhibitor of both Pyk2/FAK-CT and FAK-stimulated
motility events. Since transient expression of activated Rac
to facilitate JNK activation did not rescue FAK2/2 haptotac-
tic motility defects (data not shown), we conclude that FAK
and Pyk2/FAK-CT function to promote haptotactic motility
through the coordination of multiple signaling events specif-
ically initiated and localized at focal contact sites.
Figure 8. Focal contact localization of FAK or Pyk2/FAK-CT
specifically promotes FN-stimulated JNK activation. (A) Lysates
(50 mg) from the indicated FN-stimulated cells were blotted with
affinity-purified polyclonal antibodies to activated and phosphor-
ylated JNK and then reprobed with a polyclonal antibody to
JNK-1. (B) Human 293T cells were transiently cotransfected with
a flag-tagged JNK-1 reporter along with either control vector,
HA-FRNK, or HA-FRNK S-1034 and lysates were prepared
from either suspended (S) or FN-stimulated cells. Flag-tagged
JNK-1 in vitro kinase activity was measured in flag tag IPs by the
phosphorylation of GST-c-Jun and visualized by autoradiogra-
phy. Expression of flag-JNK-1 was visualized by flag blotting and
FRNK expression was visualized by HA-tag blotting.Klingbeil et al. Analyses of Pyk2/FAK Chimeras in FAK-null Cells 107
Discussion
Although many of the proposed molecular mechanisms
regarding FAK function in promoting cell motility have
been based on results generated either by overexpression
or dominant-negative type of experiments (Cary and
Guan, 1999), the full rescue of FAK2/2 cell morphology
and motility defects was accomplished by stable reexpres-
sion of epitope-tagged FAK at levels much lower than en-
dogenous FAK expression in FAK1/1 fibroblasts (Sieg et
al., 1999, 2000). Here, we have addressed the issue as to
why Pyk2 expression in FAK2/2 cells does not compensate
for the loss of FAK. To this end, we stably expressed chi-
meric Pyk2/FAK proteins in FAK2/2 cells at levels either
less than or equal to FAK expression in FAK1/1 cells. We
found that FAK-CT domain–mediated targeting of the
Pyk2 kinase and NT domains to b1-integrin–containing fo-
cal contact sites rescued morphological, FN-stimulated sig-
naling, and haptotactic motility defects of FAK2/2 cells.
Stable Pyk2/FAK-CT Expression Rescues FAK2/2 
Morphological Defects
Endogenous and exogenously expressed Pyk2 is perinu-
clear distributed in FAK2/2 cells, whereas the Pyk2-NT
and kinase domains fused to the FAK-CT domain as a chi-
meric protein localized to focal contact sites and promoted
FN-stimulated cell motility equivalent to FAK. FAK2/2
cells exhibit an overabundance of cortical actin structures,
a greater number of perimeter focal contact sites, and are
unable to readily assume a pointed or elongated morphol-
ogy (Sieg et al., 1999). Stable FAK reexpression results in
the dynamic rearrangement of cortical and filamentous ac-
tin structures leading to enhanced cell spreading. One tar-
get for these FAK-mediated effects is the small GTPase
Rho, the activity of which is transiently inhibited when
cells are plated onto FN (Ren et al., 1999). The inhibition
of Rho activity may alleviate contractile forces that would
otherwise impede cell protrusive activity at the leading
edge of migrating cells. Recent studies have shown that
integrin engagement suppresses RhoA activity in part
through Src-family PTK-mediated phosphorylation and
activation of p190RhoGAP (Arthur et al., 2000). How-
ever, the proposed mechanism of Rho regulation is com-
plicated by the fact that Src-family PTK activity is elevated
upon FN stimulation of FAK2/2 cells (Sieg et al., 1998)
and these cells fail to transiently inhibit Rho activity when
plated onto FN (Ren et al., 2000).
Stable FAK reconstitution restores the normal FN-stimu-
lated regulation of Rho activity and also promotes an en-
hanced rate of focal contact turnover (Ren et al., 2000). Al-
though the exact mechanism(s) of FAK-mediated Rho
inhibition are not known, the targeting of active Src to focal
contact sites has been shown to promote the turnover of
these structures during cell motility (Fincham and Frame,
1998). It is the FAK-mediated recruitment of Src-family
PTKs into a signaling complex that is an important event
promoting FN-stimulated cell migration (Sieg et al., 1999).
Significantly, we found that the FAK-CT–mediated target-
ing of the Pyk2 kinase and NT domains (Pyk2/FAK-CT) to
focal contact sites in CA3 and CB4 cells is sufficient to pro-
mote cell protrusive activity, focal contact turnover, and
normal levels of FN-stimulated cell migration equivalent to
FAK-reconstituted cells. Importantly, exogenous expres-
sion of the FAK-CT domain alone in FAK2/2 cells does not
promote these changes (Sieg et al., 1999). Whereas other
studies have found that Pyk2 and FAK may promote differ-
ential downstream signaling events (Schaller and Sasaki,
1997; Xiong and Parsons, 1997; Zhao et al., 2000), our find-
Figure 9. FRNK expression inhibits FN-stimulated ERK2 activa-
tion and Pyk2/FAK-CT haptotactic motility. (A) Human 293T
cells were transiently cotransfected with a flag-tagged ERK2 re-
porter along with either control vector, FAK, FAK plus FRNK,
or F-397 FAK and lysates were prepared from either suspended
or FN-stimulated cells. FAK and FRNK expression was verified
by HA tag blotting and FAK tyrosine phosphorylation was ana-
lyzed by FAK–NT domain–directed antibody IPs followed by
P.Tyr blotting. ERK2 in vitro kinase activity was measured in
flag tag IPs by the phosphorylation of MBP and visualized by au-
toradiography. The amount of 32P incorporated into MBP was
determined by Cerenkov counting, and the values represent the
mean from two independent experiments. (B) CA3 cells were
transiently cotransfected with 2.5 mg pCDNA3.1 Lac-Z and ei-
ther control vector, FRNK, or FRNK S-1034 (5 mg in
pCDNA3.1) and analyzed in FN haptotaxis assays (3 h). Trans-
fected and migratory cells were identified by b-gal staining and
counted. Data represent the mean 6 SD of three independent
experiments. FRNK and Pyk2/FAK-CT expression was verified
by HA tag blotting of WCLs.The Journal of Cell Biology, Volume 152, 2001 108
ings show that conserved elements within Pyk2-NT and
kinase domains can functionally substitute for FAK in
promoting FN-stimulated cell motility and that it is the in-
tracellular localization of Pyk2 or FAK that may determine
signaling specificity and biological function.
FAK-CT Connections to Focal Contacts and to a
b1-Integrin–containing Complex
The FAK-CT domain promotes the redistribution of the
Pyk2-NT and kinase domains to focal contacts in FAK2/2
cells, whereas the Pyk2-CT domain does not share this
function. Introduction of a point mutation that disrupted
paxillin binding to the FAK-CT domain (S-1034) (Tach-
ibana et al., 1995; Sieg et al., 1999) prevented Pyk2/
FAK-CT S-1034 localization to focal contact sites, inhib-
ited the FN-stimulated phosphorylation of Tyr-579 within
the Pyk2 kinase domain, and inactivated Pyk2/FAK-CT
function in promoting haptotactic cell motility. Since FAK
reconstitution of FAK2/2 cells does not promote changes
in the focal contact distribution of proteins such as vincu-
lin, talin, or paxillin (Sieg et al., 1999), our results support
the hypothesis that paxillin binding to the FAK-CT do-
main functions to link FAK to integrins and to enhance
FAK and/or chimeric Pyk2/FAK-CT kinase domain acti-
vation after FN stimulation of cells.
This view of a FAK and paxillin linkage differs from the
proposed and controversial effector role for paxillin ty-
rosine phosphorylation in promoting cell motility (Richard-
son et al., 1997; Petit et al., 2000; Yano et al., 2000). Not-
withstanding, our results also do not support paxillin as the
sole determinant in mediating focal contact localization and
b1-integrin association through the FAK-CT domain. This
is due to the fact that paxillin binds to the Pyk2-CT domain
(Salgia et al., 1996; Li and Earp, 1997), yet Pyk2 does not
strongly localize to focal contact sites and does not detect-
ably associate with a b1-integrin–containing complex in ly-
sates from FAK2/2 cells. Although our results with Pyk2/
FAK-CT S-1034 showed that paxillin association was neces-
sary for FN-stimulated Pyk2/FAK-CT in vivo biological ac-
tivity, this singular linkage is not sufficient to account for fo-
cal contact targeting and cell motility responses.
What may be the mechanism of FAK-CT domain–medi-
ated targeting to a b1-integrin–containing focal contact
complex? It is likely that FAK is targeted to these sites
through the stabilization of low affinity interactions. De-
terminations of the important linkages can be complicated
by the fact that transient overexpression can drive paxillin
binding mutants of FAK to focal contact sites (Sieg et al.,
1999), whereas we found that similar mutants stably ex-
pressed in FAK2/2 cells at lower levels are perinuclear lo-
calized. Previous studies have hypothesized that talin
binding provides an integrin-specific link mediating FAK
targeting and activation (Zheng et al., 1998). Although we
found that constructs containing the FAK-CT but not
Pyk2-CT domain associated with talin in vivo, FAK S-1034
also showed strong talin binding yet no detectable associa-
tion with a b1-integrin–containing complex. Although it is
possible that a specific, yet unknown protein binds to the
FAK-CT domain to facilitate a linkage to the b1-integrin,
it is also plausible that the combined binding of proteins
such as paxillin and talin to the FAK-CT domain facili-
tates b1-integrin association, high affinity focal contact lo-
calization, and the ability of FAK or Pyk2/FAK-CT to
promote FN-stimulated cell motility. This conclusion is
supported by the fact that either the lack of talin associa-
tion to Pyk2 or the lack of paxillin binding to FAK S-1034
disrupts the linkage to the b1-integrin.
FAK and Pyk2/FAK-CT Connections to Downstream 
Signaling Pathways Promoting Cell Motility
The mechanism(s) through which FAK promotes integrin-
stimulated signaling events to targets such as the ERK2
(Zhao et al., 1998; Schlaepfer et al., 1999) or JNK (Oktay
et al., 1999; Almeida et al., 2000) is mired in controversy
(Giancotti and Ruoslahti, 1999; Zhao et al., 2000). This is
due to the fact that many results are based on either over-
expression analyses or effects obtained by expression of
dominant-negative inhibitors. Importantly, recent studies
using primary fibroblasts from knockout mice have shown
that neither FAK (Sieg et al., 1998) nor important adaptor
proteins such as Shc (Lai and Pawson, 2000) are essential
for FN-stimulated signaling promoting ERK2 activation.
Nonetheless, FAK2/2 cells exhibit reduced FN-stimulated
ERK2 activation compared with FAK1/1 cells (Sieg et al.,
1998; Renshaw et al., 1999) and FN stimulation of FAK2/2
cells does not result in detectable JNK activation (Lebrun
et al., 2000). Here we show that stable FAK and Pyk2/
FAK-CT expression in FAK2/2 cells restored FN-stimu-
lated activation of both ERK and JNK kinase cascades to
normal levels. Importantly, these gain-of-function results
were obtained from DA2 and CA3 cells where HA-FAK
and Pyk2/FAK-CT expression are at levels significantly
less than FAK in FAK1/1 cells.
We show that the extent and duration of FN-stimulated
ERK2 activation are increased by stable FAK and Pyk2/
FAK-CT expression in FAK2/2 cells and that pharmaco-
logical inhibition of ERK2 activity prevents haptotactic
motility. Targets for activated ERK2 involved in promot-
ing cell motility include myosin light chain kinase, and ex-
pression of constitutively activated MEK1 can increase
random cell motility (Klemke et al., 1997; Gu et al., 1999).
However, expression of activated Raf kinase or MEK1 to
facilitate signaling to ERK2 did not result in the rescue of
FAK2/2 haptotactic defects. We conclude from these re-
sults that ERK2 activation is necessary but not sufficient
to promote FAK2/2 haptotactic motility. Accordingly, we
speculate that other signaling connections to FAK and
Pyk2/FAK-CT are required to initiate cell migration and
to this end, we found that FAK and Pyk2/FAK-CT specifi-
cally promoted FN-stimulated JNK activation in FAK2/2
cells. Signals leading to JNK activation have been con-
nected to enhanced cell motility (Xia et al., 2000). How-
ever, expression of activated Rac to facilitate JNK activa-
tion in FAK2/2 cells did not result in increased haptotactic
motility. From these results, we conclude that FAK and
Pyk2/FAK-CT activate multiple signaling pathways re-
quired for haptotactic motility and/or these PTKs function
to coordinate the formation of migration-promoting sig-
naling complexes localized at focal contact sites.
Localization of Signaling Complexes Is Important
for Function
Importantly, we showed that focal contact–associated Pyk2/
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S-1034 facilitated and rescued FN-stimulated haptotactic
motility of FAK2/2 cells. It is possible that FAK and Pyk2/
FAK-CT serve to coordinate and facilitate the formation of
motility-promoting signaling complex(es) at focal contact
sites that could also contain a fraction of activated ERK2
and activated JNK at these sites (Almeida et al., 2000; Fin-
cham et al., 2000). Since we have been unsuccessful in visu-
alizing the specific recruitment of either activated ERK or
JNK to focal contact sites in FN-stimulated DA2 cells
(Hauck, C.R., unpublished results), it is also possible that
the focal contact–localized complexes coordinated by FAK
or Pyk2/FAK-CT increase the efficiency of FN-stimulated
ERK and JNK activation. Nonetheless, FRNK overexpres-
sion inhibited both FN-stimulated ERK and JNK activation
as well as Pyk2/FAK-CT–stimulated haptotactic motility,
whereas control expression of FRNK S-1034, which does
not strongly localize to focal contact sites, did not inhibit ei-
ther FN-stimulated signaling or motility.
In conclusion, our results suggest that when targeted to
focal contacts, common SH2 or SH3 binding proteins to
both FAK and Pyk2 function in a complex to enhance
FAK2/2 cell motility. Recruitment of common interacting
proteins such as Src-family PTKs (Sieg et al., 1999, 2000)
and p130Cas (Cary et al., 1998; Klemke et al., 1998) may be
the first of several events in the generation of a focal con-
tact–associated signaling complex promoting motility sig-
nals. As it has been shown that signals generated by
p130Cas tyrosine phosphorylation and ERK2 activation can
synergize to enhance cell motility (Cheresh et al., 1999),
we speculate that FAK functions upstream of p130Cas and
ERK2 to coordinate these motility-promoting signaling
events. By characterizing the effects of stable and low level
expression of various FAK mutants in the FAK2/2 cell
background, it should be possible in future studies to de-
termine whether FAK-mediated activation of one or sev-
eral signaling pathways is needed to promote focal contact
remodeling events and efficient haptotactic cell migration.
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